Loading clinical trials...
Loading clinical trials...
A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
Conditions
Interventions
Dinutuximab
Locations
18
United States
University Of Alabama At Birmingham
Birmingham, Alabama, United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
Children's Hospital of Orange County
Orange, California, United States
Rady Children's Hospital- San Diego
San Diego, California, United States
University of Chicago
Chicago, Illinois, United States
Start Date
March 15, 2016
Primary Completion Date
December 19, 2016
Completion Date
December 19, 2016
Last Updated
August 5, 2019
NCT04936529
NCT06541262
NCT04851119
NCT03363373
NCT03050268
NCT05890781
Lead Sponsor
United Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions